Abstract
In this paper are presented predictions on the evolution in time of the number of positive cases in Italy of the Covid-19 pandemic based on official data and on the use of a function of the type of a Gauss Error Function as a Cumulative Distribution Function (CDF). We have analyzed the available data for China and Italy. The evolution in time of the number of cumulative diagnosed positive cases of Covid-19 in China very well approximates a distribution of the type of the Error Function, that is, the integral of a normal, Gaussian distribution. We have then used such a function to study the potential evolution in time of the number of positive cases in Italy by performing a number of fits of the official data so far available. We then found a statistical prediction for the day in which the peak of the number of daily positive cases in Italy occurs, corresponding to the flex of the fit, i.e., to the change in sign of its second derivative (that is the change from acceleration to deceleration) as well as of the day in which a substantial attenuation of such number of daily cases is reached. We have then performed 150 Monte Carlo simulations in the attempt to have a more robust prediction of the day of the above-mentioned peak and of the day of the substantial decrease of the number of daily positive cases. Although, official data have been used, these predictions are obtained with a heuristic approach, since those predictions are based on statistical approach and do not take into account either a number of relevant issues (such as medical, social distancing, virologic, epidemiological, etc.) or models of contamination diffusion.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not received any funding for the paper.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos